Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chemoresistance is one of the major obstacles in systemic chemotherapy and targeted therapy for patients with advanced hepatocellular carcinoma. To identify novel chemoresistance-associated targets in hepatocellular carcinoma, chemoresistant hepatocellular carcinoma cell lines were established. By comparing the global gene expression profiles between chemoresistant and chemosensitive cell lines, eight novel chemoresistance-associated genes were identified to be significantly associated with the commonly augmented chemoresistance of hepatocellular carcinoma cells. One upregulated candidate named
transmembrane protein 98
(
TMEM98
) was found to be overexpressed in 80 of 118 (67.80%) of patients with hepatocellular carcinoma.
TMEM98
mRNA in tumor tissues was significantly higher than nontumor tissues of patients with hepatocellular carcinoma (P < 0.0001). Upregulation of
TMEM98
was significantly correlated with advanced tumor stage (P = 0.048), high incidence of early tumor recurrence (P = 0.005), poor overall survival (P = 0.029), and poor disease-free survival (P = 0.011) of patients with hepatocellular carcinoma after hepatectomy. Importantly, upregulation of
TMEM98
mRNA in patients with hepatocellular carcinoma who received transarterial chemoembolization (TACE) treatment was significantly higher than in patients without TACE treatment (P = 0.046). Moreover, patients with poor response to TACE treatment had higher degree of
TMEM98
upregulation than the responsive patients. In vitro and in vivo studies showed that suppression of
TMEM98
in chemoresistant hepatocellular carcinoma cells restored their chemosensitivity, while forced overexpression of
TMEM98
enhanced their chemoresistance. The mechanism of
TMEM98
in conferring chemoresistance of hepatocellular carcinoma might be possibly through activation of the AKT pathway and deactivation of
p53
. In conclusion, we identified a panel of novel common chemoresistance-associated genes and demonstrated that
TMEM98
is a chemoresistance-conferring gene in hepatocellular carcinoma.
...
PMID:Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma. 2460 72